Holen Sie sich die Stockscreener-App
5.76
0.35%
-0.02
Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Why Verve Therapeutics Zoomed 40% Higher This Week - MSN
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - MSN
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News - Yahoo Finance
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' - Seeking Alpha
Verve Therapeutics (VERV) Stock Soars on Positive Trial Results - GuruFocus
Cantor Fitzgerald Upgrades Verve Therapeutics (VERV) - MSN
Verve impresses investors with second shot at PCSK9 - BioCentury
Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade - marketscreener.com
Why Verve Therapeutics Is Skyrocketing Today - The Globe and Mail
Guggenheim raises Verve Therapeutics stock target to $24 By Investing.com - Investing.com Canada
Verve stock rises as Cantor Fitzgerald upgrades (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics Shakes Market with New Genomic Breakthrough - timothysykes.com
Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral - marketscreener.com
Guggenheim Boosts Price Target for Verve Therapeutics (VERV) to $24 | VERV Stock News - GuruFocus
Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results - insights.citeline.com
Early stage cardio data from Verve bump the stock - BioWorld MedTech
Assessing Verve Therapeutics: Insights From 4 Financial Analysts - Benzinga
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data - Yahoo Finance
This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life. - Barron's
Verve shares soar after new gene-editing trial shows no safety concerns - The Boston Globe
Verve Therapeutics: FDA Nod Sparks Stock Surge - timothysykes.com
Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose - Benzinga
Verve Therapeutics: A New Era in Cardiovascular Disease Treatment? - RagingBull
Verve’s second swing at gene editing for heart disease shows early promise - BioPharma Dive
Verve Shares Soar After New Gene-Editing Trial Shows No Safety Concerns - Bloomberg.com
Verve Therapeutics Stock Rise: Is It A Turning Point? - timothysykes.com
Verve stock jumps on early-stage trial data (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics' VERVE-102 Gene Editing Therapy Trial Shows Positive Initial Data in Clinical Trial - marketscreener.com
Verve Therapeutics reports promising trial results for cholesterol drug By Investing.com - Investing.com Canada
Verve Therapeutics reports promising trial results for cholesterol drug - Investing.com Australia
Verve Therapeutics stock soars on positive clinical trial results By Investing.com - Investing.com Nigeria
Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 - Yahoo Home
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics LawsuitVERV - ACCESS Newswire
Verve stock gains on FDA fast track tag (VERV:NASDAQ) - Seeking Alpha
Verve Therapeutics Gets FDA Fast Track Designation for VERVE-102 - MarketScreener
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 - The Manila Times
Verve Therapeutics Receives U.S. FDA Fast Track Designation For Verve-102, An In Vivo Base Editing Medicine Targeting Pcsk9 - MarketScreener
Verve Therapeutics Receives U.S. FDA Fast Track Designation - GlobeNewswire
Revolutionary Gene Editing Drug for Heart Disease Earns FDA Fast Track Status - Stock Titan
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):